**Supplemental Table 2 | Demographic characteristics of people who have been performed single-cell sequencing**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 　 | Normal Range | Longer duration infection | Shorter duration infection | Healthy donors |
| 　 | 　 | LT1 | LT2 | LT3 | LT4 | LT5 | ST1 | ST2 | ST3 | ST4 | HD1 | HD2 | HD3 |
| **Sequenced cell number** | 　 | 12485 | 11022 | 10352 | 13487 | 10063 | 8740 | 8641 | 11080 | 8244 | 9630 | 10316 | 10546 |
| **Characteristics** | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 |
| Age (years) | 　 | 64 | 54 | 58 | 36 | 55 | 57 | 59 | 74 | 59 | 36 | 43 | 29 |
| Gender | 　 | M | F | F | F | F | F | F | F | M | F | F | F |
| Symptoms onset | 　 | Fever, cough | Cough, fatigue | Fever,cough, Chills | Sore throat, cough, fatigue | Fever, fatigue, cough, short of breath | Fever | Fever, cough, chills, fatigue | Fever | Fever, Diarrhea | NA | NA | NA |
| Severity | 　 | general | general | general | severe | critical | severe | general | critical | general | NA | NA | NA |
| Duration of viral shedding, days | 　 | 88 | 100 | 54 | 76 | 77 | 2 | 4 | 22 | 3 | NA | NA | NA |
| Onset of symptom to sampling, days | 　 | 90 | 102 | 56 | 78 | 80 | 98 | 89 | 70 | 85 | NA | NA | NA |
| **Blood routine** | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 |
| leukocyte, × 10⁹/L | 3.50-9.50 | 6.31 | 6.11 | 4.81 | 4.21 | 5.41 | 7.78 | 5.09 | 3.62 | 5.95 | NA | NA | NA |
| neutrophil, % | 40.0-75.0 | 55.6 | 57.6 | 64.6 | 61.5 | 63.3 | 58 | 54.5 | 62.7 | 58.1 | NA | NA | NA |
| neutrophil,× 10⁹/L | 1.80-6.30 | 3.51 | 3.52 | 3.11 | 2.59 | 3.42 | 4.51 | 2.77 | 2.77 | 3.46 | NA | NA | NA |
| lymphocyte, % | 20.0-50.0 | 31.5 | 33.4 | 28.9 | 30.6 | 28.8 | 29.3 | 32.4 | 21 | 22.2 | NA | NA | NA |
| lymphocyte,× 10⁹/L | 1.10-3.20 | 1.99 | 2.04 | 1.39 | 1.29 | 1.56 | 2.28 | 1.65 | 0.76 | 1.32 | NA | NA | NA |
| monocyte, % | 3.0-10.0 | 9.5 | 7.22 | 4.2 | 5 | 5.5 | 7.6 | 8.6 | 11.9 | 11.8 | NA | NA | NA |
| monocyte,× 10⁹/L | 0.10-0.60 | 0.6 | 0.44 | 0.2 | 0.21 | 0.3 | 0.59 | 0.44 | 0.43 | 0.7 | NA | NA | NA |
| eosinophil, % | 0.4-8.0 | 2.9 | 1.3 | 1.9 | 2.4 | 2 | 4.5 | 4.1 | 4.1 | 7.7 | NA | NA | NA |
| eosinophil,× 10⁹/L | 0.02-0.52 | 0.18 | 0.08 | 0.09 | 0.1 | 0.11 | 0.35 | 0.21 | 0.15 | 0.46 | NA | NA | NA |
| basophilic granulocyte,% | 0.0-1.0 | 0.5 | 0.5 | 0.4 | 0.5 | 0.4 | 0.6 | 0.4 | 0.3 | 0.2 | NA | NA | NA |
| basophilic granulocyte,× 10⁹/L | 0.00-0.10 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.05 | 0.02 | 0.01 | 0.01 | NA | NA | NA |
| PLT, × 10⁹/L | 125.0-350.0 | 139 | 235 | 137 | 208 | 214 | 230 | 179 | 224 | 278 | NA | NA | NA |
| **Coagulation function** |  | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 |
| Prothrombin time, s | 11.5-14.5 | 15.6 | 14.4 | NA | 13.9 | 13.5 | 13.2 | 13.8 | 12.9 | 13.2 | NA | NA | NA |
| Prothrombin Time and International Normalized Ratio (PT/INR) | 0.80-1.20 | 1.23 | 1.12 | NA | 1.06 | 1.03 | 0.99 | 1.05 | 0.96 | 1 | NA | NA | NA |
| Fibrinogen, g/L | 2.00-4.00 | 2.69 | 3.39 | NA | 2.27 | 3.38 | 3.67 | 2.96 | 3.16 | 3.13 | NA | NA | NA |
| Activated partial thromboplastin, s | 29-42 | 39.6 | 37.9 | NA | 39 | 34.8 | 38.4 | 40.6 | 45.4 | 40.4 | NA | NA | NA |
| Thrombin time, s | 14-19 | 15.9 | 16.7 | NA | 14.9 | 14.7 | 16.5 | 16.8 | 14.6 | 14.6 | NA | NA | NA |
| D-dimer, μg/ml | <0.5 | <0.22 | 0.53 | NA | <0.22 | 0.69 | 0.32 | <0.22 | 0.54 | 0.25 | NA | NA | NA |